Journal: PloS one

Article Title: Reduced selenium-binding protein 1 in breast cancer correlates with poor survival and resistance to the anti-proliferative effects of selenium.

doi: 10.1371/journal.pone.0063702

Figure Lengend Snippet: Figure 1. The Expression of SELENBP1 in Normal and Tumor Breast Tissues. Breast cancer tissue arrays were stained by immunohistochemistry using anti-human SELENBP1 antibody at 1:100 dilution. Positive stained cells are shown in dark brown color. (A) Strong positive staining of SELENBP1 in normal breast tissue under low power view (200X). (B–C) Weak positive to negative staining of SELENBP1 in breast cancer tissues under high power view (400X). (D) The Allred scoring distributions of SELENBP1 expression in normal and tumor tissue groups. Inside lines represent means and standard deviations. *p,0.05. (E) Statistical results for the difference between normal and tumor tissues as analyzed by Kruskal-Wallis test. doi:10.1371/journal.pone.0063702.g001

Article Snippet: Breast Cancer Tissue Array Slides Three sets of breast cancer tissue arrays (including normal, primary tumor, and metastases) were obtained from Imgenex or Biomax Inc.

Techniques: Expressing, Staining, Immunohistochemistry, Negative Staining

Journal: PloS one

Article Title: Reduced selenium-binding protein 1 in breast cancer correlates with poor survival and resistance to the anti-proliferative effects of selenium.

doi: 10.1371/journal.pone.0063702

Figure Lengend Snippet: Figure 2. SELENBP1 Expression is Progressively Reduced in Advancing Clinical Stages in Breast Cancer Tissues. (A) The scoring distributions of SELENBP1 expression in normal tissues and tumor tissues at stage II and stage III. Inside lines represent means and standard deviations. **p,0.01. (B) Statistical results for the difference between normal and tumor tissues as analyzed by Kruskal-Wallis test. (C) Survival curves of breast cancer patients with respect to different SELENBP1 expression levels are shown at stage II and (D) stage III. Blue and red lines represent the SELENBP1-high and SELENBP1-low groups, respectively. doi:10.1371/journal.pone.0063702.g002

Article Snippet: Breast Cancer Tissue Array Slides Three sets of breast cancer tissue arrays (including normal, primary tumor, and metastases) were obtained from Imgenex or Biomax Inc.

Techniques: Expressing

Journal: PloS one

Article Title: Reduced selenium-binding protein 1 in breast cancer correlates with poor survival and resistance to the anti-proliferative effects of selenium.

doi: 10.1371/journal.pone.0063702

Figure Lengend Snippet: Figure 3. The Correlation of SELENBP1 Expression with ER, PR, and TP53 in Breast Cancer Tissues. (A) The scoring distributions of SELENBP1 expression in normal tissues and tumor tissues with ER+ and ER– status. The inside lines represent means and standard deviations. **p,0.01. The difference between normal and ER+ and ER– tumor tissues was analyzed by Kruskal-Wallis test and statistical results are shown (B). Survival curves of breast cancer patients with respect to different SELENBP1 expression are shown in ER+ group in (C). The blue line is the SELENBP1- high group and the red line is the SELENBP1-low group. The scoring distributions of SELENBP1 expression in normal and tumor tissues with PR+/PR–

Article Snippet: Breast Cancer Tissue Array Slides Three sets of breast cancer tissue arrays (including normal, primary tumor, and metastases) were obtained from Imgenex or Biomax Inc.

Techniques: Expressing

Journal: International journal of cancer

Article Title: Neuropilin-1 is differentially expressed in myoepithelial cells and vascular smooth muscle cells in preneoplastic and neoplastic human breast: a possible marker for the progression of breast cancer.

doi: 10.1002/ijc.10611

Figure Lengend Snippet: FIGURE 5 – Detection of mRNA for NRP-1 in formalin-fixed paraffin-embedded human breast tissue sections by in situ hybridization using DIG labeled PCR generated exon or intron specific probes. The purple color indicates the expression of NRP-1 mRNA. Sections were counter stained with nuclear first red. (a) Normal breast tissue section illustrating negative staining, which was observed in most normal breast tissue sections. Magnification 300. (b) Benign duct adjacent to the invasive carcinoma cells. Arrows, myoepithe- lial cells expressing NRP-1 mRNA; arrow heads, epithelial cells that do not express NRP-1. Magni- fication 300. (c) Negative control. Section was hybridized with an intron-specific DIG-labeled PCR generated probe. Magnification 400. (d) Blood vessels from invasive carcinoma section. The arrows point to vascular SMC expressing NRP-1 mRNA. Arrow heads, endothelial cells. Magnification 300.

Article Snippet: Formalin-fixed and paraffin-embedded human breast tissue array slides (Imgenex Co., CA.) were also analyzed for the present studies.

Techniques: In Situ Hybridization, Labeling, Generated, Expressing, Staining, Negative Staining, Negative Control

Journal: Oncotarget

Article Title: Downregulation of BRCA1-BRCA2-containing complex subunit 3 sensitizes glioma cells to temozolomide

doi:

Figure Lengend Snippet: Human brain tissue slide used for this study contained 24 cases of patients with different grades of gliomas in duplicates. The tissue slide was subjected to immunohistochemistry staining using anti-BRCC3 antibody (Abcam). The representative images show BRCC3 immunoreactivity in normal human cortical tissue (A) grade I astrocytoma (B) grade II astrocytoma (C) grade III anaplastic astrocytoma (D) grade IV glioblastoma multiforme (E) . Experiments were repeated using anti-BRCC3 antibody from ProSci with similar observations. The staining was photographed under microscope with four images taken from each case. BRCC3 immunoreactivity of normal brain tissue and different grades of glioma were evaluated using ImageJ software (F) . Cells with BRCC3 immunostaining were selected through threshold setting of ImageJ software. The data are referred as immunoreactivity score (IRS) representing the average intensity of BRCC3-positive cells normalized over the intensity of background. ** p < 0.01, versus normal tissue. Scale bar in A-E, 100 μm.

Article Snippet: Human brain tumor tissue slide (Pantomics Inc., Richmond, CA, USA) was first heated at 60 ° C for 30 min before deparaffinization using xylene.

Techniques: Immunohistochemistry, Staining, Microscopy, Software, Immunostaining

Journal: Cancer Medicine

Article Title: An antibody‐drug conjugate targeting a GSTA glycosite‐signature epitope of MUC1 expressed by non‐small cell lung cancer

doi: 10.1002/cam4.3554

Figure Lengend Snippet: Staining of non‐small cell lung cancer (NSCLC) cells and tissues by 16A (specific to GSTA neoantigen), SM3, and C595 (specific to PDTR neoantigen). (A) NSCLC cell lines were stained with 16A, SM3, and C595 antibodies. (B) Tissue array slides containing consecutive tissue sections from the same NSCLC patients were stained with 16A, SM3, and C595 antibodies.

Article Snippet: Tumor tissue array slides were obtained from CrownBio.

Techniques: Staining

Journal: Cancer Medicine

Article Title: An antibody‐drug conjugate targeting a GSTA glycosite‐signature epitope of MUC1 expressed by non‐small cell lung cancer

doi: 10.1002/cam4.3554

Figure Lengend Snippet: Expression of the aberrantly glycosylated MUC1 peptide motif in lung and breast cancer tissues upon 16A antibody staining. (A) H‐score of the cancer tissue array stained with the 16A antibody. The intensity of IHC staining was scored at four levels: 0 (negative), 1 (weak staining), 2 (medium staining), and 3 (strong staining). The percentages of tumor cells at different intensity levels were evaluated. Total Score = (% at 0) ×0 + (% at 1) × 1 + (% at 2) ×2 + (% at 3) × 3. (B) 16A positivity in lung cancer, breast cancer, and triple‐negative breast cancer (TNBC) samples. (C, D, E, F) Representative photographs of MUC1 immunostaining in peritumoral (C), lung cancer (D), Non‐TNBC (E), and TNBC (F) tissue with the 16A antibody (original magnification ×200). Positivity was defined as ≥30% of tumor with staining ≥2+.

Article Snippet: Tumor tissue array slides were obtained from CrownBio.

Techniques: Expressing, Staining, Immunohistochemistry, Immunostaining